4-chloro-3,5-dimethyl-benzonitrile | 1097629-24-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-3,5-dimethyl-benzonitrile
• 英文别名: 4-chloro-3,5-dimethylbenzonitrile
• CAS: 1097629-24-7
• 化学式: C₉H₈ClN
• 分子量: 165.622
• InChiKey: LZOSJVOQBLCSHF-UHFFFAOYSA-N

物化性质

• 沸点：
  270.7±35.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-chloro-3,5-dimethyl-benzonitrile 在 potassium carbonate 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.25h， 生成 3,5-dimethyl-4-((2-(piperidin-4-ylamino)quinazolin-4-yl)oxy)benzonitrile
  参考文献：
  名称：

  Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility

  摘要：

  To address the intractable issues of drug resistance and poor solubility, a novel series of morpholine-substituted diarylpyrimidines targeting the tolerant region I and tolerant region II of NNIBP were rationally designed by utilizing the available crystallography studies. The biological evaluation results showed that four most promising compounds (14e1, 14g1, 14g2 and 14j2) displayed excellent potency against WT HIV-1 strain with EC(50 )values ranging from 58 to 87 nM, being far more potent than NVP and comparable to ETV. Besides, some derivatives exhibited moderate activity in inhibiting the mutant HIV-1 strains. More encouragingly, 14d2 (RF = 0.4) possessed higher antiresistance profile than ETV (RF = 6.3) and K-5a2 (RF = 3.0) toward the double mutant strain F227L + V106A. The HIV-1 RT inhibition assay confirmed their binding target. The molecular docking studies were conducted and discussed in detail to rationalize the preliminary SARs. Further test indicated that morpholine could indeed promote the improvement of water solubility. Additionally, the in silico prediction of physicochemical properties and CYP enzymatic inhibitory ability were investigated to evaluate their drug-like features. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112811
• 作为产物：
  描述：

  4-氨基-3,5-二甲基苯氰 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以89%的产率得到4-chloro-3,5-dimethyl-benzonitrile
  参考文献：
  名称：

  [EN] NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
  [FR] NOUVEAUX INHIBITEURS DE LA TRANSCRIPTASE INVERSE DU VIH

  摘要：

  公开号：

  WO2009005674A3

文献信息

• Biaryl Benzylamine Derivatives
  申请人：Angst Daniela

  公开号：US20100168079A1

  公开（公告）日：2010-07-01

  The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及双芳基-苄基胺化合物，其生产方法，作为药物的应用，以及包含它们的药物组合物。
• Dual Ligand-Enabled Nondirected C–H Cyanation of Arenes
  作者：Hao Chen、Arup Mondal、Philipp Wedi、Manuel van Gemmeren

  DOI：10.1021/acscatal.8b04639

  日期：2019.3.1

  structural units in organic chemistry and, therefore, highly attractive targets for C–H activation. Herein, the development of an arene-limited, nondirected C–H cyanation based on the use of two cooperatively acting commercially available ligands is reported. The reaction enables the cyanation of arenes by C–H activation in the absence of directing groups and is therefore complementary to established

  芳香腈是有机化学中的关键结构单元，因此是C–H活化的极具吸引力的目标。在此，据报道，基于使用两种可协同作用的市售配体，开发了一种受芳烃限制的，无方向性的CH氰基氰化反应。该反应可在没有导向基团的情况下通过C–H活化使芳烃氰化，因此可与已建立的方法互补。
• Novel HIV reverse transcriptase inhibitors
  申请人：Guo Hongyan

  公开号：US20110076276A1

  公开（公告）日：2011-03-31

  The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及以下化合物的公式（I）：或其药学上可接受的盐、溶剂化物、酯和/或膦酸酯，包含这些化合物的组合物以及包括这些化合物的给药的治疗方法。
• ARYL BENZYLAMINE COMPOUNDS
  申请人：ANGST Daniela

  公开号：US20110190258A1

  公开（公告）日：2011-08-04

  The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及取代芳基苄胺化合物，其生产过程，其作为药物的用途以及包含它们的药物组成物。
• Pyrimidine derivatives as HIV reverse transcriptase inhibitors
  申请人：Korea Research Institute of Chemical Technology

  公开号：US08334295B2

  公开（公告）日：2012-12-18

  The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及式（I）化合物：或其药学上可接受的盐、溶剂化物、酯和/或膦酸酯，含有这种化合物的组合物以及包括这种化合物的给药的治疗方法。